Home CellPoint

CellPoint

acquired
-
Tumor CAR-T Cell Therapy Drug Developer

Basic Information

CellPoint B.V. enables clinicians to treat hematologic malignancies by redirecting patients' immune cells at the point of care, aiming to provide affordable and readily available CAR-T therapy for all patients in need, focusing on quality and patient safety while reducing treatment time and costs through point-of-care automation.
CellPoint B.V.
SouthHolland,Netherlands
less than 15 people
January 01, 2018
info@cellpoint.bio